RT Journal Article
SR Electronic
T1 Nasal systems immunology identifies inflammatory and tolerogenic myeloid cells that determine allergic outcome following challenge
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.09.20189886
DO 10.1101/2020.09.09.20189886
A1 Astrid L. Voskamp
A1 Maarten L. Gerdes
A1 Roberta Menafra
A1 Ellen Duijster
A1 Szymon M. Kielbasa
A1 Tom Groot Kormelink
A1 Tamar Tak
A1 Koen A. Stam
A1 Nicolette W. de Jong
A1 Rudi W. Hendriks
A1 Suzanne L. Kloet
A1 Maria Yazdanbakhsh
A1 Esther C. de Jong
A1 Roy Gerth van Wijk
A1 Hermelijn H. Smits
YR 2021
UL http://medrxiv.org/content/early/2021/04/27/2020.09.09.20189886.abstract
AB Innate mononuclear phagocytic system (MPS) cells preserve mucosal immune homeostasis. Here, we investigated their role at nasal mucosa following challenge with house dust mite. We combined single cell proteome and transcriptome profiling on immune cells from nasal biopsy cells of allergic rhinitis and non-allergic subjects, before and after repeated nasal allergen challenge. Nasal biopsies of patients showed infiltrating inflammatory HLA-DRhi CD14+ monocytes and CD16+ monocytes, and transcriptional changes in resident CD1C+ CD1A+ conventional dendritic cells (cDC)2 following challenge. Importantly, although clinically silent, non-allergic individuals displayed a distinct innate MPS response to allergen challenge: predominant infiltration of myeloid-derived suppressor cells (HLA-DRlow CD14+ monocytes), as well as cDC2 clusters expressing increased inhibitory/tolerogenic transcripts. Therefore, we identified not only clusters involved in airway inflammation but also a non-inflammatory, homeostatic blueprint of innate MPS responses to allergens in non-allergic individuals. Future therapies should target innate MPS for treatment of inflammatory airway diseases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by a consortiumgrant of the Dutch Long Foundation (Grant ID: 5.1.15.015)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All subjects gave written informed consent and research was conducted in compliance with all relevant ethical regulations. Ethical approval was given by Eramsus Medical Centre Ethics Committee in Rotterdam (MEC2016-560).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data will be made available upon reasonable requests.